Literature DB >> 17307394

Is excitation-contraction coupling impaired in myasthenia gravis?

Miho Nakata1, Satoshi Kuwabara, Naoki Kawaguchi, Hirokatsu Takahashi, Sonoko Misawa, Kazuaki Kanai, Noriko Tamura, Setsu Sawai, Masakatsu Motomura, Hirokazu Shiraishi, Masaharu Takamori, Takahiro Maruta, Hiroaki Yoshikawa, Takamichi Hattori.   

Abstract

OBJECTIVE: To investigate whether excitation-contraction (E-C) coupling of muscle is impaired in patients with myasthenia gravis (MG).
METHODS: In 51 patients with generalized MG and 35 normal subjects, compound muscle action potentials (CMAPs) of the abductor pollicis brevis, and movement-related potentials using an accelerometer placed at the thumb tip were simultaneously recorded after median nerve stimulation at the wrist. The E-C coupling time (ECCT) was estimated by a latency difference between CMAP and movement-related potential. Antibodies against acetylcholine receptor (AChR), ryanodine receptor (RyR), and muscle specific receptor tyrosine kinase (MuSK) were measured by immunoassays.
RESULTS: The mean ECCT was significantly longer in patients with MG (mean+/-SEM; 2.79+/-0.1 ms; p=0.002) than in normal controls (2.52+/-0.1 ms). Among MG patients, the mean ECCT was longer for patients with thymoma than for those without it (P=0.04), and was shorter for patients treated with FK506 (an immunosuppressant and also an enhancer of RyR related Ca(2+) release) than for those not receiving this treatment (p=0.04). ECCT had no significant correlation with anti-AChR, anti-RyR, or anti-MuSK antibodies.
CONCLUSIONS: In MG, E-C coupling appears to be impaired, particularly in patients with thymoma, and FK506 possibly facilitates E-C coupling. SIGNIFICANCE: The functional implication of impaired E-C coupling is not established, but it may contribute to muscle weakness in patients with MG.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17307394     DOI: 10.1016/j.clinph.2007.01.001

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  2 in total

1.  In response to "current approach to seronegative myasthenia" by Z. Argov.

Authors:  Michal Haran
Journal:  J Neurol       Date:  2010-11-18       Impact factor: 4.849

2.  Three types of striational antibodies in myasthenia gravis.

Authors:  Shigeaki Suzuki; Kimiaki Utsugisawa; Yuriko Nagane; Norihiro Suzuki
Journal:  Autoimmune Dis       Date:  2011-07-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.